Ticker Hub
MIRM — AI Analysis & Sentiment
5 recent AI-generated analyses for MIRM. Sentiment and confidence insights updated continuously.
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Positive Phase 2b results for volixibat de-risk a key pipeline asset, creating significant long-term revenue potential in an underserved rare disea...
May 4, 2026Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals met the primary endpoint in its Phase 2b study for brelovitug, a key pipeline asset for chronic HDV. This positive clinical d...
Apr 27, 2026Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals' completion of Phase 3 enrollment for LIVMARLI expands its market potential, signaling progress towards increased revenue. Th...
Mar 17, 2026Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals announced key Phase 3 trial milestones for brelovitug, advancing its HDV treatment pipeline.
Mar 5, 2026Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
Mirum Pharmaceuticals delivered strong 2025 financial results with significant revenue growth and reduced net losses, coupled with optimistic 2026 ...
Feb 27, 2026